Naxitamab
Opportunity for indication expansion
Neuroblastoma and other related tumors are associated with overexpression of GD2, a disialoganglioside that has limited expression on normal cells.1 Naxitamab is a humanized monoclonal antibody (mAB) that can bind to GD2 and trigger immune-mediated cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).2
We continue to advance our naxitamab platform with the belief that naxitamab has the potential to treat a broad range of cancers, including osteosarcoma, soft-tissue sarcomas, triple-negative breast cancer, and melanoma.
Naxitamab Pipeline
STUDY
Therapeautic Areas
PRECLINICAL
PHASE I
PHASE II/
PIVOTAL
SPONSOR
Status
201
Relapsed/Refractory High-Risk Neuroblastoma (Pediatric)
Preclinical
Phase I
Y-mAbs
FDA Accelerated Approval and Recruiting
Relapsed/Refractory High-Risk Neuroblastoma
Preclinical
Phase I
Dana-Farber Cancer Institute
Preclinical
Phase I
Beat Childhood Cancer Research Consortium
OSU-22237
(with gemcitabine and TGFBi NK cells)
Preclinical
Phase I
Ohio State University Comprehensive Cancer Center
Preclinical
Phase I
Preclinical
Phase I
Relapsed/Refractory High-Risk Neuroblastoma
Preclinical
Phase I
Completed
Relapsed/Refractory High-Risk Neuroblastoma
Preclinical
Phase I
Completed
Newly Diagnosed High-Risk Neuroblastoma
Preclinical
Phase I
Preclinical
Phase I